Overview

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This research study is studying a drug called Palbociclib in combination with Bazedoxifene (a type of endocrine therapy, which prevents breast cancer cell growth by blocking estrogen stimulation) as a possible treatment for this diagnosis. The names of the study interventions involved in this study are: - Palbociclib - Bazedoxifene

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Pfizer

Treatments:

Bazedoxifene
Hormones
Palbociclib